{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:53:35Z","timestamp":1781643215324,"version":"3.54.5"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.neurot.2026.e00888","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T19:32:17Z","timestamp":1774035137000},"page":"e00888","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["No association between the wearing-off effect and \u03b14-integrin receptor saturation in natalizumab treated patients with relapsing-remitting multiple sclerosis"],"prefix":"10.1016","volume":"23","author":[{"given":"Sean A.","family":"Freeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Rual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Biotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Lepetit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Le Berre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylynne","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Treiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ciron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.neurot.2026.e00888_bib1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e00888_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231221331","article-title":"Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies","volume":"17","author":"Butzkueven","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00888_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7224\/1537-2073.2013-017","article-title":"Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle","volume":"16","author":"Ratchford","year":"2014","journal-title":"Int J MS Care"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00888_bib4","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00888_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40120-023-00440-5","article-title":"Real-World effectiveness of natalizumab extended interval dosing in a French cohort","volume":"12","author":"Pelle","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurot.2026.e00888_bib6","first-page":"458","article-title":"Natalizumab extended interval dosing: what about wearing-off effect?","author":"Bernardes","year":"2024","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00888_bib7","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000678","article-title":"Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy","volume":"7","author":"Bringeland","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"17","key":"10.1016\/j.neurot.2026.e00888_bib8","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008357","article-title":"The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms","volume":"93","author":"Van Kempen","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00888_bib9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/cyto.a.23723","article-title":"Optimization of receptor occupancy assays in mass cytometry: standardization across channels with QSC beads","volume":"95","author":"Bringeland","year":"2019","journal-title":"Cytometry A"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00888_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.12969","article-title":"CNS inflammation after natalizumab therapy for multiple sclerosis: a retrospective histopathological and CSF cohort study","volume":"31","author":"H\u00e4usler","year":"2021","journal-title":"Brain Pathol"},{"key":"10.1016\/j.neurot.2026.e00888_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jneuroim.2016.12.013","article-title":"Fatigue favors in vitro Th1 and Th17-like cell expansion and reduces corticoid sensitivity in MS patients","volume":"303","author":"Alvarenga-Filho","year":"2017","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00888_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-2377-12-95","article-title":"TH1\/TH2 cytokine profile in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate or natalizumab","volume":"12","author":"Oreja-Guevara","year":"2012","journal-title":"BMC Neurol"},{"key":"10.1016\/j.neurot.2026.e00888_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jneuroim.2017.06.012","article-title":"Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis","volume":"310","author":"Villani","year":"2017","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurot.2026.e00888_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.msard.2019.03.017","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing","volume":"31","author":"Foley","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00888_bib15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/cyto.b.21527","article-title":"Monitoring CD49d receptor occupancy: a method to optimize and personalize natalizumab therapy in multiple sclerosis patients","volume":"94","author":"Pu\u00f1et-Ortiz","year":"2018","journal-title":"Cytometry B Clin Cytometry"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00888_bib16","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/jcph.894","article-title":"Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis","volume":"57","author":"Muralidharan","year":"2017","journal-title":"J Clin Pharmacol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:05:34Z","timestamp":1781640334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926000589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1878747926000589"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00888","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No association between the wearing-off effect and \u03b14-integrin receptor saturation in natalizumab treated patients with relapsing-remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00888","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00888"}}